nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—LIPF—digestive system—colon cancer	0.0427	0.141	CbGeAlD
Orlistat—PLA2G7—lymphoid tissue—colon cancer	0.0174	0.0574	CbGeAlD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—colon cancer	0.017	1	CbGdCrCtD
Orlistat—DAGLB—liver—colon cancer	0.0159	0.0523	CbGeAlD
Orlistat—PLA2G7—bone marrow—colon cancer	0.0159	0.0523	CbGeAlD
Orlistat—PLA2G7—vagina—colon cancer	0.0152	0.0501	CbGeAlD
Orlistat—PNLIP—digestive system—colon cancer	0.0151	0.0499	CbGeAlD
Orlistat—ABHD16A—bone marrow—colon cancer	0.0149	0.0491	CbGeAlD
Orlistat—ABHD16A—vagina—colon cancer	0.0143	0.047	CbGeAlD
Orlistat—ABHD12—vagina—colon cancer	0.0134	0.044	CbGeAlD
Orlistat—PLA2G7—liver—colon cancer	0.0128	0.0423	CbGeAlD
Orlistat—DAGLB—lymph node—colon cancer	0.0122	0.0401	CbGeAlD
Orlistat—PNLIP—liver—colon cancer	0.0113	0.0372	CbGeAlD
Orlistat—ABHD12—liver—colon cancer	0.0113	0.0372	CbGeAlD
Orlistat—FASN—vagina—colon cancer	0.0112	0.037	CbGeAlD
Orlistat—PLA2G7—lymph node—colon cancer	0.00983	0.0324	CbGeAlD
Orlistat—FASN—liver—colon cancer	0.00946	0.0312	CbGeAlD
Orlistat—ABHD16A—lymph node—colon cancer	0.00923	0.0304	CbGeAlD
Orlistat—ABHD12—lymph node—colon cancer	0.00865	0.0285	CbGeAlD
Orlistat—PLA2G4A—smooth muscle tissue—colon cancer	0.00773	0.0255	CbGeAlD
Orlistat—PLA2G4A—renal system—colon cancer	0.00744	0.0245	CbGeAlD
Orlistat—FASN—lymph node—colon cancer	0.00726	0.0239	CbGeAlD
Orlistat—PLA2G4A—bone marrow—colon cancer	0.00563	0.0185	CbGeAlD
Orlistat—PLA2G4A—vagina—colon cancer	0.00539	0.0178	CbGeAlD
Orlistat—PLA2G4A—lymph node—colon cancer	0.00349	0.0115	CbGeAlD
Orlistat—CYP3A4—renal system—colon cancer	0.00246	0.00809	CbGeAlD
Orlistat—CYP3A4—digestive system—colon cancer	0.00201	0.00664	CbGeAlD
Orlistat—Dermatitis bullous—Capecitabine—colon cancer	0.00191	0.00405	CcSEcCtD
Orlistat—Urethral disorder—Vincristine—colon cancer	0.00189	0.00403	CcSEcCtD
Orlistat—Haemoglobin—Irinotecan—colon cancer	0.00189	0.00402	CcSEcCtD
Orlistat—Sinusitis—Fluorouracil—colon cancer	0.00188	0.00401	CcSEcCtD
Orlistat—Haemorrhage—Irinotecan—colon cancer	0.00188	0.004	CcSEcCtD
Orlistat—Arthritis—Capecitabine—colon cancer	0.00187	0.00398	CcSEcCtD
Orlistat—Vaginal inflammation—Methotrexate—colon cancer	0.00187	0.00397	CcSEcCtD
Orlistat—Osteoarthritis—Capecitabine—colon cancer	0.00182	0.00387	CcSEcCtD
Orlistat—Haemoglobin—Fluorouracil—colon cancer	0.00181	0.00385	CcSEcCtD
Orlistat—Haemorrhage—Fluorouracil—colon cancer	0.0018	0.00383	CcSEcCtD
Orlistat—Pharyngitis—Fluorouracil—colon cancer	0.00179	0.00381	CcSEcCtD
Orlistat—Vaginal infection—Methotrexate—colon cancer	0.00176	0.00375	CcSEcCtD
Orlistat—Mediastinal disorder—Vincristine—colon cancer	0.00174	0.0037	CcSEcCtD
Orlistat—Alopecia—Vincristine—colon cancer	0.00171	0.00363	CcSEcCtD
Orlistat—Immune system disorder—Irinotecan—colon cancer	0.0017	0.00362	CcSEcCtD
Orlistat—Mediastinal disorder—Irinotecan—colon cancer	0.0017	0.00361	CcSEcCtD
Orlistat—Mental disorder—Vincristine—colon cancer	0.00169	0.0036	CcSEcCtD
Orlistat—Neoplasm—Methotrexate—colon cancer	0.00169	0.00359	CcSEcCtD
Orlistat—Urine output increased—Methotrexate—colon cancer	0.00169	0.00359	CcSEcCtD
Orlistat—Dry skin—Capecitabine—colon cancer	0.00167	0.00355	CcSEcCtD
Orlistat—Alopecia—Irinotecan—colon cancer	0.00166	0.00354	CcSEcCtD
Orlistat—Abdominal pain upper—Capecitabine—colon cancer	0.00166	0.00354	CcSEcCtD
Orlistat—Hypokalaemia—Capecitabine—colon cancer	0.00166	0.00352	CcSEcCtD
Orlistat—Breast disorder—Capecitabine—colon cancer	0.00165	0.0035	CcSEcCtD
Orlistat—Back pain—Vincristine—colon cancer	0.00163	0.00346	CcSEcCtD
Orlistat—Flatulence—Irinotecan—colon cancer	0.00161	0.00343	CcSEcCtD
Orlistat—Gastritis—Capecitabine—colon cancer	0.00161	0.00343	CcSEcCtD
Orlistat—Alopecia—Fluorouracil—colon cancer	0.00159	0.00339	CcSEcCtD
Orlistat—Back pain—Irinotecan—colon cancer	0.00159	0.00337	CcSEcCtD
Orlistat—Abdominal distension—Capecitabine—colon cancer	0.00158	0.00337	CcSEcCtD
Orlistat—Muscle spasms—Irinotecan—colon cancer	0.00158	0.00335	CcSEcCtD
Orlistat—Influenza—Capecitabine—colon cancer	0.00157	0.00335	CcSEcCtD
Orlistat—Asthma—Capecitabine—colon cancer	0.00157	0.00335	CcSEcCtD
Orlistat—Diabetes mellitus—Methotrexate—colon cancer	0.00156	0.00331	CcSEcCtD
Orlistat—Bronchospasm—Capecitabine—colon cancer	0.00155	0.00329	CcSEcCtD
Orlistat—Polyuria—Methotrexate—colon cancer	0.00154	0.00328	CcSEcCtD
Orlistat—Sweating increased—Capecitabine—colon cancer	0.00153	0.00326	CcSEcCtD
Orlistat—Ill-defined disorder—Irinotecan—colon cancer	0.00152	0.00323	CcSEcCtD
Orlistat—Vertigo—Vincristine—colon cancer	0.00151	0.00321	CcSEcCtD
Orlistat—Abdominal discomfort—Capecitabine—colon cancer	0.00151	0.00321	CcSEcCtD
Orlistat—Hepatic failure—Methotrexate—colon cancer	0.00151	0.00321	CcSEcCtD
Orlistat—CYP3A4—liver—colon cancer	0.0015	0.00494	CbGeAlD
Orlistat—Vision blurred—Fluorouracil—colon cancer	0.00148	0.00315	CcSEcCtD
Orlistat—Malaise—Irinotecan—colon cancer	0.00148	0.00314	CcSEcCtD
Orlistat—Vertigo—Irinotecan—colon cancer	0.00147	0.00313	CcSEcCtD
Orlistat—Upper respiratory tract infection—Capecitabine—colon cancer	0.00146	0.00311	CcSEcCtD
Orlistat—Convulsion—Vincristine—colon cancer	0.00146	0.0031	CcSEcCtD
Orlistat—Myalgia—Vincristine—colon cancer	0.00143	0.00305	CcSEcCtD
Orlistat—Cough—Irinotecan—colon cancer	0.00143	0.00304	CcSEcCtD
Orlistat—Infestation NOS—Capecitabine—colon cancer	0.0014	0.00298	CcSEcCtD
Orlistat—Infestation—Capecitabine—colon cancer	0.0014	0.00298	CcSEcCtD
Orlistat—Depression—Capecitabine—colon cancer	0.0014	0.00298	CcSEcCtD
Orlistat—Renal failure—Capecitabine—colon cancer	0.00138	0.00293	CcSEcCtD
Orlistat—Discomfort—Irinotecan—colon cancer	0.00138	0.00293	CcSEcCtD
Orlistat—Neuropathy peripheral—Capecitabine—colon cancer	0.00138	0.00293	CcSEcCtD
Orlistat—Anaphylactic shock—Vincristine—colon cancer	0.00137	0.00292	CcSEcCtD
Orlistat—Oedema—Vincristine—colon cancer	0.00137	0.00292	CcSEcCtD
Orlistat—Infection—Vincristine—colon cancer	0.00136	0.0029	CcSEcCtD
Orlistat—Urinary tract infection—Capecitabine—colon cancer	0.00136	0.0029	CcSEcCtD
Orlistat—Convulsion—Fluorouracil—colon cancer	0.00136	0.00289	CcSEcCtD
Orlistat—Osteoarthritis—Methotrexate—colon cancer	0.00136	0.00288	CcSEcCtD
Orlistat—Nervous system disorder—Vincristine—colon cancer	0.00135	0.00286	CcSEcCtD
Orlistat—Anaphylactic shock—Irinotecan—colon cancer	0.00134	0.00284	CcSEcCtD
Orlistat—Oedema—Irinotecan—colon cancer	0.00134	0.00284	CcSEcCtD
Orlistat—Chest pain—Fluorouracil—colon cancer	0.00134	0.00284	CcSEcCtD
Orlistat—Myalgia—Fluorouracil—colon cancer	0.00134	0.00284	CcSEcCtD
Orlistat—Infection—Irinotecan—colon cancer	0.00133	0.00283	CcSEcCtD
Orlistat—Hyperhidrosis—Vincristine—colon cancer	0.00133	0.00282	CcSEcCtD
Orlistat—Hepatobiliary disease—Capecitabine—colon cancer	0.00133	0.00282	CcSEcCtD
Orlistat—Discomfort—Fluorouracil—colon cancer	0.00132	0.00281	CcSEcCtD
Orlistat—Nervous system disorder—Irinotecan—colon cancer	0.00131	0.00279	CcSEcCtD
Orlistat—Hyperhidrosis—Irinotecan—colon cancer	0.00129	0.00275	CcSEcCtD
Orlistat—Oedema—Fluorouracil—colon cancer	0.00128	0.00272	CcSEcCtD
Orlistat—Anaphylactic shock—Fluorouracil—colon cancer	0.00128	0.00272	CcSEcCtD
Orlistat—Infection—Fluorouracil—colon cancer	0.00127	0.00271	CcSEcCtD
Orlistat—Haemoglobin—Capecitabine—colon cancer	0.00127	0.00269	CcSEcCtD
Orlistat—Haemorrhage—Capecitabine—colon cancer	0.00126	0.00268	CcSEcCtD
Orlistat—Hepatitis—Capecitabine—colon cancer	0.00126	0.00268	CcSEcCtD
Orlistat—Nervous system disorder—Fluorouracil—colon cancer	0.00126	0.00267	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Vincristine—colon cancer	0.00125	0.00266	CcSEcCtD
Orlistat—Pharyngitis—Capecitabine—colon cancer	0.00125	0.00266	CcSEcCtD
Orlistat—Urinary tract disorder—Capecitabine—colon cancer	0.00124	0.00265	CcSEcCtD
Orlistat—Insomnia—Vincristine—colon cancer	0.00124	0.00264	CcSEcCtD
Orlistat—Oedema peripheral—Capecitabine—colon cancer	0.00124	0.00264	CcSEcCtD
Orlistat—Urethral disorder—Capecitabine—colon cancer	0.00123	0.00263	CcSEcCtD
Orlistat—Paraesthesia—Vincristine—colon cancer	0.00123	0.00262	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—colon cancer	0.00123	0.00261	CcSEcCtD
Orlistat—Insomnia—Irinotecan—colon cancer	0.00121	0.00257	CcSEcCtD
Orlistat—Paraesthesia—Irinotecan—colon cancer	0.0012	0.00255	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—colon cancer	0.00119	0.00254	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—colon cancer	0.00119	0.00252	CcSEcCtD
Orlistat—Fatigue—Vincristine—colon cancer	0.00118	0.00252	CcSEcCtD
Orlistat—Dyspepsia—Irinotecan—colon cancer	0.00118	0.0025	CcSEcCtD
Orlistat—Pain—Vincristine—colon cancer	0.00117	0.0025	CcSEcCtD
Orlistat—Asthma—Methotrexate—colon cancer	0.00117	0.00249	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00117	0.00248	CcSEcCtD
Orlistat—Decreased appetite—Irinotecan—colon cancer	0.00116	0.00247	CcSEcCtD
Orlistat—Insomnia—Fluorouracil—colon cancer	0.00116	0.00246	CcSEcCtD
Orlistat—Gastrointestinal disorder—Irinotecan—colon cancer	0.00115	0.00246	CcSEcCtD
Orlistat—Fatigue—Irinotecan—colon cancer	0.00115	0.00245	CcSEcCtD
Orlistat—Paraesthesia—Fluorouracil—colon cancer	0.00115	0.00245	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—colon cancer	0.00115	0.00244	CcSEcCtD
Orlistat—Pain—Irinotecan—colon cancer	0.00114	0.00243	CcSEcCtD
Orlistat—Immune system disorder—Capecitabine—colon cancer	0.00114	0.00242	CcSEcCtD
Orlistat—Mediastinal disorder—Capecitabine—colon cancer	0.00114	0.00241	CcSEcCtD
Orlistat—Dyspepsia—Fluorouracil—colon cancer	0.00113	0.0024	CcSEcCtD
Orlistat—Abdominal discomfort—Methotrexate—colon cancer	0.00112	0.00239	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—colon cancer	0.00112	0.00239	CcSEcCtD
Orlistat—Decreased appetite—Fluorouracil—colon cancer	0.00111	0.00237	CcSEcCtD
Orlistat—Alopecia—Capecitabine—colon cancer	0.00111	0.00237	CcSEcCtD
Orlistat—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00111	0.00235	CcSEcCtD
Orlistat—Mental disorder—Capecitabine—colon cancer	0.0011	0.00235	CcSEcCtD
Orlistat—Feeling abnormal—Irinotecan—colon cancer	0.0011	0.00234	CcSEcCtD
Orlistat—Malnutrition—Capecitabine—colon cancer	0.0011	0.00233	CcSEcCtD
Orlistat—Pain—Fluorouracil—colon cancer	0.0011	0.00233	CcSEcCtD
Orlistat—Gastrointestinal pain—Irinotecan—colon cancer	0.00109	0.00233	CcSEcCtD
Orlistat—Upper respiratory tract infection—Methotrexate—colon cancer	0.00109	0.00232	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—colon cancer	0.00109	0.00231	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—colon cancer	0.00109	0.00231	CcSEcCtD
Orlistat—Flatulence—Capecitabine—colon cancer	0.00108	0.0023	CcSEcCtD
Orlistat—Dysgeusia—Capecitabine—colon cancer	0.00107	0.00228	CcSEcCtD
Orlistat—Back pain—Capecitabine—colon cancer	0.00106	0.00226	CcSEcCtD
Orlistat—Body temperature increased—Irinotecan—colon cancer	0.00106	0.00225	CcSEcCtD
Orlistat—Abdominal pain—Irinotecan—colon cancer	0.00106	0.00225	CcSEcCtD
Orlistat—Feeling abnormal—Fluorouracil—colon cancer	0.00106	0.00224	CcSEcCtD
Orlistat—Muscle spasms—Capecitabine—colon cancer	0.00105	0.00224	CcSEcCtD
Orlistat—Infestation—Methotrexate—colon cancer	0.00104	0.00222	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—colon cancer	0.00104	0.00222	CcSEcCtD
Orlistat—Depression—Methotrexate—colon cancer	0.00104	0.00222	CcSEcCtD
Orlistat—Vision blurred—Capecitabine—colon cancer	0.00103	0.0022	CcSEcCtD
Orlistat—Renal failure—Methotrexate—colon cancer	0.00103	0.00218	CcSEcCtD
Orlistat—Ill-defined disorder—Capecitabine—colon cancer	0.00102	0.00216	CcSEcCtD
Orlistat—Urticaria—Fluorouracil—colon cancer	0.00102	0.00216	CcSEcCtD
Orlistat—Body temperature increased—Fluorouracil—colon cancer	0.00101	0.00215	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—colon cancer	0.00101	0.00215	CcSEcCtD
Orlistat—Malaise—Capecitabine—colon cancer	0.000989	0.0021	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—colon cancer	0.000988	0.0021	CcSEcCtD
Orlistat—Vertigo—Capecitabine—colon cancer	0.000985	0.0021	CcSEcCtD
Orlistat—Hypersensitivity—Irinotecan—colon cancer	0.000985	0.0021	CcSEcCtD
Orlistat—Asthenia—Vincristine—colon cancer	0.000985	0.0021	CcSEcCtD
Orlistat—Palpitations—Capecitabine—colon cancer	0.000969	0.00206	CcSEcCtD
Orlistat—Asthenia—Irinotecan—colon cancer	0.000959	0.00204	CcSEcCtD
Orlistat—Cough—Capecitabine—colon cancer	0.000957	0.00204	CcSEcCtD
Orlistat—Hypersensitivity—Fluorouracil—colon cancer	0.000944	0.00201	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—colon cancer	0.000943	0.002	CcSEcCtD
Orlistat—Diarrhoea—Vincristine—colon cancer	0.00094	0.002	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—colon cancer	0.000938	0.00199	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—colon cancer	0.000938	0.00199	CcSEcCtD
Orlistat—Myalgia—Capecitabine—colon cancer	0.000934	0.00199	CcSEcCtD
Orlistat—Chest pain—Capecitabine—colon cancer	0.000934	0.00199	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—colon cancer	0.000931	0.00198	CcSEcCtD
Orlistat—Anxiety—Capecitabine—colon cancer	0.00093	0.00198	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000927	0.00197	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—colon cancer	0.000926	0.00197	CcSEcCtD
Orlistat—Discomfort—Capecitabine—colon cancer	0.000922	0.00196	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—colon cancer	0.000919	0.00196	CcSEcCtD
Orlistat—Diarrhoea—Irinotecan—colon cancer	0.000915	0.00195	CcSEcCtD
Orlistat—Dry mouth—Capecitabine—colon cancer	0.000913	0.00194	CcSEcCtD
Orlistat—Dizziness—Vincristine—colon cancer	0.000908	0.00193	CcSEcCtD
Orlistat—Pruritus—Fluorouracil—colon cancer	0.000906	0.00193	CcSEcCtD
Orlistat—Oedema—Capecitabine—colon cancer	0.000895	0.0019	CcSEcCtD
Orlistat—Infection—Capecitabine—colon cancer	0.000889	0.00189	CcSEcCtD
Orlistat—Dizziness—Irinotecan—colon cancer	0.000884	0.00188	CcSEcCtD
Orlistat—Nervous system disorder—Capecitabine—colon cancer	0.000878	0.00187	CcSEcCtD
Orlistat—Diarrhoea—Fluorouracil—colon cancer	0.000876	0.00186	CcSEcCtD
Orlistat—Vomiting—Vincristine—colon cancer	0.000873	0.00186	CcSEcCtD
Orlistat—Skin disorder—Capecitabine—colon cancer	0.000869	0.00185	CcSEcCtD
Orlistat—Rash—Vincristine—colon cancer	0.000866	0.00184	CcSEcCtD
Orlistat—Hyperhidrosis—Capecitabine—colon cancer	0.000865	0.00184	CcSEcCtD
Orlistat—Dermatitis—Vincristine—colon cancer	0.000865	0.00184	CcSEcCtD
Orlistat—Headache—Vincristine—colon cancer	0.00086	0.00183	CcSEcCtD
Orlistat—Vomiting—Irinotecan—colon cancer	0.00085	0.00181	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—colon cancer	0.000847	0.0018	CcSEcCtD
Orlistat—Dizziness—Fluorouracil—colon cancer	0.000847	0.0018	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—colon cancer	0.000845	0.0018	CcSEcCtD
Orlistat—Rash—Irinotecan—colon cancer	0.000843	0.00179	CcSEcCtD
Orlistat—Dermatitis—Irinotecan—colon cancer	0.000842	0.00179	CcSEcCtD
Orlistat—Headache—Irinotecan—colon cancer	0.000838	0.00178	CcSEcCtD
Orlistat—Alopecia—Methotrexate—colon cancer	0.000829	0.00176	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—colon cancer	0.000822	0.00175	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—colon cancer	0.000816	0.00174	CcSEcCtD
Orlistat—Nausea—Vincristine—colon cancer	0.000816	0.00173	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000815	0.00173	CcSEcCtD
Orlistat—Vomiting—Fluorouracil—colon cancer	0.000814	0.00173	CcSEcCtD
Orlistat—Insomnia—Capecitabine—colon cancer	0.00081	0.00172	CcSEcCtD
Orlistat—Rash—Fluorouracil—colon cancer	0.000808	0.00172	CcSEcCtD
Orlistat—Dermatitis—Fluorouracil—colon cancer	0.000807	0.00172	CcSEcCtD
Orlistat—Paraesthesia—Capecitabine—colon cancer	0.000804	0.00171	CcSEcCtD
Orlistat—Headache—Fluorouracil—colon cancer	0.000802	0.00171	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—colon cancer	0.000799	0.0017	CcSEcCtD
Orlistat—Nausea—Irinotecan—colon cancer	0.000794	0.00169	CcSEcCtD
Orlistat—Back pain—Methotrexate—colon cancer	0.00079	0.00168	CcSEcCtD
Orlistat—Dyspepsia—Capecitabine—colon cancer	0.000788	0.00168	CcSEcCtD
Orlistat—Decreased appetite—Capecitabine—colon cancer	0.000778	0.00165	CcSEcCtD
Orlistat—Gastrointestinal disorder—Capecitabine—colon cancer	0.000773	0.00164	CcSEcCtD
Orlistat—Fatigue—Capecitabine—colon cancer	0.000772	0.00164	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—colon cancer	0.000769	0.00164	CcSEcCtD
Orlistat—Pain—Capecitabine—colon cancer	0.000765	0.00163	CcSEcCtD
Orlistat—Nausea—Fluorouracil—colon cancer	0.000761	0.00162	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—colon cancer	0.000757	0.00161	CcSEcCtD
Orlistat—Feeling abnormal—Capecitabine—colon cancer	0.000738	0.00157	CcSEcCtD
Orlistat—Malaise—Methotrexate—colon cancer	0.000736	0.00157	CcSEcCtD
Orlistat—Vertigo—Methotrexate—colon cancer	0.000733	0.00156	CcSEcCtD
Orlistat—Gastrointestinal pain—Capecitabine—colon cancer	0.000732	0.00156	CcSEcCtD
Orlistat—Cough—Methotrexate—colon cancer	0.000712	0.00152	CcSEcCtD
Orlistat—Urticaria—Capecitabine—colon cancer	0.000711	0.00151	CcSEcCtD
Orlistat—Abdominal pain—Capecitabine—colon cancer	0.000708	0.0015	CcSEcCtD
Orlistat—Body temperature increased—Capecitabine—colon cancer	0.000708	0.0015	CcSEcCtD
Orlistat—Convulsion—Methotrexate—colon cancer	0.000707	0.0015	CcSEcCtD
Orlistat—Myalgia—Methotrexate—colon cancer	0.000695	0.00148	CcSEcCtD
Orlistat—Chest pain—Methotrexate—colon cancer	0.000695	0.00148	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00069	0.00147	CcSEcCtD
Orlistat—Discomfort—Methotrexate—colon cancer	0.000687	0.00146	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—colon cancer	0.000666	0.00142	CcSEcCtD
Orlistat—Infection—Methotrexate—colon cancer	0.000662	0.00141	CcSEcCtD
Orlistat—Hypersensitivity—Capecitabine—colon cancer	0.000659	0.0014	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—colon cancer	0.000653	0.00139	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—colon cancer	0.000647	0.00138	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—colon cancer	0.000644	0.00137	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—AKT1—colon cancer	0.000643	0.00307	CbGpPWpGaD
Orlistat—Asthenia—Capecitabine—colon cancer	0.000642	0.00137	CcSEcCtD
Orlistat—Pruritus—Capecitabine—colon cancer	0.000633	0.00135	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000632	0.00302	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—BRAF—colon cancer	0.000628	0.003	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000628	0.003	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000625	0.00299	CbGpPWpGaD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000615	0.00294	CbGpPWpGaD
Orlistat—Diarrhoea—Capecitabine—colon cancer	0.000612	0.0013	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—CTNNB1—colon cancer	0.000612	0.00293	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000607	0.00129	CcSEcCtD
Orlistat—Insomnia—Methotrexate—colon cancer	0.000603	0.00128	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—EGFR—colon cancer	0.0006	0.00287	CbGpPWpGaD
Orlistat—Paraesthesia—Methotrexate—colon cancer	0.000598	0.00127	CcSEcCtD
Orlistat—Dizziness—Capecitabine—colon cancer	0.000592	0.00126	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—colon cancer	0.000587	0.00125	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—colon cancer	0.000579	0.00123	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—colon cancer	0.000575	0.00122	CcSEcCtD
Orlistat—Fatigue—Methotrexate—colon cancer	0.000574	0.00122	CcSEcCtD
Orlistat—Pain—Methotrexate—colon cancer	0.00057	0.00121	CcSEcCtD
Orlistat—Vomiting—Capecitabine—colon cancer	0.000569	0.00121	CcSEcCtD
Orlistat—Rash—Capecitabine—colon cancer	0.000564	0.0012	CcSEcCtD
Orlistat—Dermatitis—Capecitabine—colon cancer	0.000564	0.0012	CcSEcCtD
Orlistat—Headache—Capecitabine—colon cancer	0.000561	0.00119	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PIK3CA—colon cancer	0.000554	0.00265	CbGpPWpGaD
Orlistat—Feeling abnormal—Methotrexate—colon cancer	0.000549	0.00117	CcSEcCtD
Orlistat—DAGLA—Hemostasis—EP300—colon cancer	0.000548	0.00262	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—EP300—colon cancer	0.000548	0.00262	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Methotrexate—colon cancer	0.000545	0.00116	CcSEcCtD
Orlistat—DAGLA—Hemostasis—SRC—colon cancer	0.000533	0.00255	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SRC—colon cancer	0.000533	0.00255	CbGpPWpGaD
Orlistat—Nausea—Capecitabine—colon cancer	0.000532	0.00113	CcSEcCtD
Orlistat—Urticaria—Methotrexate—colon cancer	0.000529	0.00113	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—colon cancer	0.000527	0.00112	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—colon cancer	0.000527	0.00112	CcSEcCtD
Orlistat—DAGLB—Hemostasis—VEGFA—colon cancer	0.000519	0.00248	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—VEGFA—colon cancer	0.000519	0.00248	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NRAS—colon cancer	0.000513	0.00245	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NRAS—colon cancer	0.000513	0.00245	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—colon cancer	0.000513	0.00245	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—HRAS—colon cancer	0.0005	0.00239	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000497	0.00238	CbGpPWpGaD
Orlistat—Hypersensitivity—Methotrexate—colon cancer	0.000491	0.00104	CcSEcCtD
Orlistat—Asthenia—Methotrexate—colon cancer	0.000478	0.00102	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TGFB1—colon cancer	0.000477	0.00228	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TGFB1—colon cancer	0.000477	0.00228	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000476	0.00228	CbGpPWpGaD
Orlistat—Pruritus—Methotrexate—colon cancer	0.000471	0.001	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—ODC1—colon cancer	0.000465	0.00222	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CHST5—colon cancer	0.000465	0.00222	CbGpPWpGaD
Orlistat—Diarrhoea—Methotrexate—colon cancer	0.000456	0.00097	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—colon cancer	0.000453	0.00216	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000447	0.00214	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—KRAS—colon cancer	0.000441	0.00211	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KRAS—colon cancer	0.000441	0.00211	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—AKT1—colon cancer	0.000441	0.00211	CbGpPWpGaD
Orlistat—Dizziness—Methotrexate—colon cancer	0.000441	0.000937	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000428	0.00205	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—AKT1—colon cancer	0.000425	0.00203	CbGpPWpGaD
Orlistat—Vomiting—Methotrexate—colon cancer	0.000424	0.000901	CcSEcCtD
Orlistat—Rash—Methotrexate—colon cancer	0.00042	0.000893	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—colon cancer	0.00042	0.000893	CcSEcCtD
Orlistat—Headache—Methotrexate—colon cancer	0.000417	0.000888	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000414	0.00198	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DLC1—colon cancer	0.000413	0.00198	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—SRC—colon cancer	0.00041	0.00196	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—PIK3CA—colon cancer	0.000406	0.00194	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—PIK3CA—colon cancer	0.000406	0.00194	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—ABCB1—colon cancer	0.000405	0.00193	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TYMS—colon cancer	0.000397	0.0019	CbGpPWpGaD
Orlistat—Nausea—Methotrexate—colon cancer	0.000396	0.000842	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—colon cancer	0.000395	0.00189	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—colon cancer	0.000392	0.00187	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—colon cancer	0.000392	0.00187	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LGR5—colon cancer	0.000389	0.00186	CbGpPWpGaD
Orlistat—PNLIP—Disease—FGFR3—colon cancer	0.000379	0.00181	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—colon cancer	0.000375	0.00179	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—colon cancer	0.000375	0.00179	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—colon cancer	0.000368	0.00176	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000362	0.00173	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000352	0.00168	CbGpPWpGaD
Orlistat—PNLIP—Disease—APC—colon cancer	0.000348	0.00166	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—colon cancer	0.00034	0.00162	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000336	0.0016	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—AKT1—colon cancer	0.000331	0.00158	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—AKT1—colon cancer	0.000331	0.00158	CbGpPWpGaD
Orlistat—PNLIP—Disease—BRAF—colon cancer	0.000327	0.00156	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000327	0.00156	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000324	0.00155	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—FGFR3—colon cancer	0.000321	0.00153	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—FGFR3—colon cancer	0.000321	0.00153	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000316	0.00151	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—colon cancer	0.000312	0.00149	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	0.000306	0.00146	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000301	0.00144	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—APC—colon cancer	0.000294	0.00141	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—APC—colon cancer	0.000294	0.00141	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—colon cancer	0.000294	0.00141	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—NRAS—colon cancer	0.000294	0.00141	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000293	0.0014	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000292	0.0014	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—colon cancer	0.000289	0.00138	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PIK3CA—colon cancer	0.000289	0.00138	CbGpPWpGaD
Orlistat—FASN—Metabolism—ABCB1—colon cancer	0.000286	0.00137	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000285	0.00136	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PPARG—colon cancer	0.000282	0.00135	CbGpPWpGaD
Orlistat—FASN—Metabolism—TYMS—colon cancer	0.000281	0.00134	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AXIN2—colon cancer	0.000279	0.00133	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BRAF—colon cancer	0.000277	0.00132	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BRAF—colon cancer	0.000277	0.00132	CbGpPWpGaD
Orlistat—FASN—Disease—FGFR3—colon cancer	0.000268	0.00128	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—EGFR—colon cancer	0.000268	0.00128	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—EGFR—colon cancer	0.000268	0.00128	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGFR3—colon cancer	0.000266	0.00127	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—colon cancer	0.000264	0.00126	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000262	0.00125	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000261	0.00125	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—SRC—colon cancer	0.00026	0.00124	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PIK3CA—colon cancer	0.000256	0.00122	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—PIK3CA—colon cancer	0.000256	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000256	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—colon cancer	0.000253	0.00121	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—colon cancer	0.000253	0.00121	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—colon cancer	0.000253	0.00121	CbGpPWpGaD
Orlistat—FASN—Disease—APC—colon cancer	0.000246	0.00118	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—APC—colon cancer	0.000244	0.00117	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000242	0.00116	CbGpPWpGaD
Orlistat—PNLIP—Disease—CTNNB1—colon cancer	0.000237	0.00113	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—colon cancer	0.000233	0.00111	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PIK3CA—colon cancer	0.000233	0.00111	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—colon cancer	0.000233	0.00111	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—colon cancer	0.000232	0.00111	CbGpPWpGaD
Orlistat—PNLIP—Disease—CDKN1A—colon cancer	0.000231	0.0011	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—colon cancer	0.000229	0.0011	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000222	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—colon cancer	0.000221	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Disease—EP300—colon cancer	0.00022	0.00105	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	0.000216	0.00103	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—colon cancer	0.000215	0.00103	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—colon cancer	0.000215	0.00103	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000215	0.00103	CbGpPWpGaD
Orlistat—PNLIP—Disease—SRC—colon cancer	0.000214	0.00102	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—colon cancer	0.000209	0.001	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—colon cancer	0.000209	0.001	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—colon cancer	0.000207	0.000991	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—colon cancer	0.000207	0.000991	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—colon cancer	0.000206	0.000983	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—colon cancer	0.000202	0.000965	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—colon cancer	0.000202	0.000965	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CTNNB1—colon cancer	0.0002	0.000955	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CTNNB1—colon cancer	0.0002	0.000955	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—colon cancer	0.000199	0.000952	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	0.000198	0.000946	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CDKN1A—colon cancer	0.000195	0.000933	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDKN1A—colon cancer	0.000195	0.000933	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000192	0.000917	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—colon cancer	0.000192	0.000916	CbGpPWpGaD
Orlistat—PNLIP—Disease—TGFB1—colon cancer	0.000191	0.000914	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—colon cancer	0.00019	0.000908	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—colon cancer	0.00019	0.000908	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—colon cancer	0.000187	0.000896	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—colon cancer	0.000187	0.000894	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EP300—colon cancer	0.000186	0.000888	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EP300—colon cancer	0.000186	0.000888	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—EP300—colon cancer	0.000184	0.00088	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000182	0.000868	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SRC—colon cancer	0.000181	0.000864	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SRC—colon cancer	0.000181	0.000864	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CA7—colon cancer	0.00018	0.000859	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—colon cancer	0.000177	0.000846	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—colon cancer	0.000176	0.000841	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—colon cancer	0.000176	0.000841	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—colon cancer	0.000174	0.000831	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—colon cancer	0.000174	0.000831	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—colon cancer	0.000172	0.000821	CbGpPWpGaD
Orlistat—FASN—Disease—CTNNB1—colon cancer	0.000167	0.0008	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—colon cancer	0.000167	0.000799	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CTNNB1—colon cancer	0.000166	0.000792	CbGpPWpGaD
Orlistat—FASN—Disease—CDKN1A—colon cancer	0.000164	0.000781	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—colon cancer	0.000163	0.000777	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—colon cancer	0.000162	0.000774	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—colon cancer	0.000162	0.000774	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDKN1A—colon cancer	0.000162	0.000773	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—colon cancer	0.000162	0.000773	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—colon cancer	0.000162	0.000772	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—colon cancer	0.000162	0.000772	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—colon cancer	0.000158	0.000757	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—colon cancer	0.000158	0.000757	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—colon cancer	0.000157	0.000749	CbGpPWpGaD
Orlistat—FASN—Disease—EP300—colon cancer	0.000156	0.000744	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EP300—colon cancer	0.000154	0.000736	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—colon cancer	0.000151	0.000723	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000151	0.000721	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—colon cancer	0.000151	0.000719	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—colon cancer	0.00015	0.000716	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—colon cancer	0.00015	0.000715	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—colon cancer	0.00015	0.000715	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—colon cancer	0.000146	0.000697	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—colon cancer	0.000146	0.000696	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—colon cancer	0.000144	0.000688	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—colon cancer	0.000138	0.000659	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—colon cancer	0.000137	0.000657	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—colon cancer	0.000137	0.000657	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—colon cancer	0.000136	0.000651	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—colon cancer	0.000136	0.000648	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—colon cancer	0.000135	0.000646	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—colon cancer	0.000134	0.000641	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—colon cancer	0.000134	0.000641	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—colon cancer	0.000134	0.00064	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—colon cancer	0.000133	0.000636	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—colon cancer	0.000133	0.000636	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—colon cancer	0.000133	0.000635	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—colon cancer	0.000133	0.000634	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—colon cancer	0.000131	0.000627	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—colon cancer	0.000131	0.000624	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—colon cancer	0.00013	0.000623	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—colon cancer	0.000129	0.000617	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—colon cancer	0.000127	0.000608	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—colon cancer	0.000127	0.000608	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000126	0.0006	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—colon cancer	0.000125	0.000599	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—colon cancer	0.000124	0.000593	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—colon cancer	0.000123	0.000587	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—colon cancer	0.000121	0.000577	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—colon cancer	0.00012	0.000573	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—colon cancer	0.000115	0.00055	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—colon cancer	0.000114	0.000544	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—colon cancer	0.000112	0.000537	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—colon cancer	0.000112	0.000537	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—colon cancer	0.000111	0.000532	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—colon cancer	0.000111	0.000531	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—colon cancer	0.00011	0.000527	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CHST5—colon cancer	0.000109	0.00052	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ODC1—colon cancer	0.000109	0.00052	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—colon cancer	0.000106	0.000509	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—colon cancer	0.000105	0.000504	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—colon cancer	0.000102	0.000488	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—colon cancer	9.87e-05	0.000472	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—colon cancer	9.64e-05	0.000461	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—colon cancer	9.44e-05	0.000451	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—colon cancer	9.4e-05	0.000449	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—colon cancer	9.31e-05	0.000445	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.29e-05	0.000444	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—colon cancer	8.55e-05	0.000408	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—colon cancer	8.34e-05	0.000398	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR3—colon cancer	8.07e-05	0.000385	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—colon cancer	7.87e-05	0.000376	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—colon cancer	7.41e-05	0.000354	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—colon cancer	7.41e-05	0.000354	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—colon cancer	6.96e-05	0.000333	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—colon cancer	6.75e-05	0.000322	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—colon cancer	6.72e-05	0.000321	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—colon cancer	6.37e-05	0.000305	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—colon cancer	5.86e-05	0.00028	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—colon cancer	5.59e-05	0.000267	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—colon cancer	5.42e-05	0.000259	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—colon cancer	5.22e-05	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—colon cancer	5.08e-05	0.000243	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—colon cancer	5.03e-05	0.00024	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—colon cancer	4.91e-05	0.000235	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—colon cancer	4.78e-05	0.000229	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—colon cancer	4.68e-05	0.000223	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—colon cancer	4.55e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—colon cancer	4.43e-05	0.000212	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—colon cancer	4.37e-05	0.000209	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—colon cancer	4.14e-05	0.000198	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—colon cancer	4.07e-05	0.000195	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—colon cancer	4.06e-05	0.000194	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—colon cancer	3.99e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—colon cancer	3.77e-05	0.00018	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—colon cancer	3.46e-05	0.000165	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—colon cancer	3.38e-05	0.000161	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—colon cancer	3.35e-05	0.00016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—colon cancer	3.2e-05	0.000153	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—colon cancer	2.88e-05	0.000137	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—colon cancer	2.83e-05	0.000135	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—colon cancer	2.83e-05	0.000135	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—colon cancer	2e-05	9.56e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—colon cancer	1.57e-05	7.52e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—colon cancer	1.31e-05	6.26e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—colon cancer	9.69e-06	4.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—colon cancer	7.91e-06	3.78e-05	CbGpPWpGaD
